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Abstract
Background: Fine-needle aspiration biopsy (FNAB) of the breast is a minimally invasive yet maximally diagnostic
method. However, the clinical use of FNAB has been questioned. The purpose of our study was to establish the
overall value of FNAC in the diagnosis of breast lesions.
Methods: After a review and quality assessment of 46 studies, sensitivity, specificity and other measures of
accuracy of FNAB for evaluating breast lesions were pooled using random-effects models. Summary receiver
operating characteristic curves were used to summarize overall accuracy. The sensitivity and specificity for the
studies data (included unsatisfactory samples) and underestimation rate of unsatisfactory samples were also
calculated.
Results: The summary estimates for FNAB in diagnosis of breast carcinoma were as follows (unsatisfactory samples
was temporarily exluded): sensitivity, 0.927 (95% confidence interval [CI], 0.921 to 0.933); specificity, 0.948 (95% CI,
0.943 to 0.952); positive likelihood ratio, 25.72 (95% CI, 17.35 to 28.13); negative likelihood ratio, 0.08 (95% CI, 0.06
to 0.11); diagnostic odds ratio, 429.73 (95% CI, 241.75 to 763.87); The pooled sensitivity and specificity for 11
studies, which reported unsatisfactory samples (unsatisfactory samples was considered to be positive in this
classification) were 0.920 (95% CI, 0.906 to 0.933) and 0.768 (95% CI, 0.751 to 0.784) respectively. The pooled
proportion of unsatisfactory samples that were subsequently upgraded to various grade cancers was 27.5% (95%
CI, 0.221 to 0.296).
Conclusions: FNAB is an accurate biopsy for evaluating breast malignancy if rigorous criteria are used. With regard
to unsatisfactory samples, futher invasive procedures are required in order to minimize the chance of a missed
diagnosis of breast cancer.
Introduction
Palpable breast mass is a common problem in female
patients. The diagnostic delays of breast cancer occur
due to the generally low index of suspicion. The tradi-
tional diagnosis mode of breast mass is excisional
biopsy, which gives a precise diagnosis but may yield a
benign pathological result in most cases.
Fine-needle aspiration biopsy (FNAB) of the breast is a
minimally invasive diagnostic method, often obviating an
open biopsy [1]. It is cheaper to perform and its results
can be available within a shorter time. However, the role
of FNAB has been challenged of late by better overall
results attained by core biopsies. Core biopsy is definitely
a robust and reliable diagnostic modality, but carries dis-
advantages in terms of a longer turn-around due to the
tissue processing time, and patient discomfort during the
procedure. FNAB has some advantages over core-needle
biopsy in that it use a smaller needle and thus has a
lower probability of causing hematoma and other rare
complications, such as pneumothorax [2,3]
With the introduction of stereotactic and ultrasonogra-
phically (US) guided methods for nonpalpable lesions,
fine-needle aspiration biopsy (FNAB) have been used
more widely in the evaluation of nonpalpable breast
lesions [4-6]. Furthermore, the triple-diagnostic method
(consisting of clinical evaluation, mammography and
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missed diagnosis of breast cancer to < 1% [7].
However, the clinical use of FNAB has been questioned
because of the variability in results reported [8] In addi-
tion, It is also possible that no cells are harvested making
cytological analysis impossible. Many institutes in the Uni-
ted Kingdom, the United States and Canada have now
abandoned FNA for diagnosis of breast lesions. Neverthe-
less, it continues to be used in other institutes in these
countries, as well as in Greece, Italy, Australia and Japan,
and in developing countries such as India, Pakistan,
Nigeria, Mexico and Thailand. Up to now, there was no
meta-analysis to establish the overall value of FNAB for
the diagnostic breast cancer. The purpose of our study
was to establish the overall value of FNAC in the diagnosis
of breast lesions.
Materials and methods
Search strategy and study selection
We searched MEDLINE (1966 to 2010), EMBASE (1970
to 2010), the Cochrane Central Register of Controlled
Trials (CENTRAL), database of Health Technology
Assessments on The Cochrane Library issue 2, 2010 and
the China Biological Medicine Database (CBM-disc, 1979
to 2010), VIP Chinese Journals Database (1968 to 2010),
China National Knowledge Infrastructure Whole Article
Database (CNKI, 1994 to 2010). We also searched the
trials registers of Cochrane Breast Cancer Group and the
WHO International Clinical Trials Registry at http://www.
who.int/ictrp/en/ for ongoing and recently completed
trials. All searches were up to date as of December 2010.
The search terms used were “breast neoplasms”, “fine-nee-
dle aspiration biopsy”, “Sensitivity and Specificity” and
“accuracy”. In addition, related keywords and their syno-
nyms were included in our search strategy and reference
lists were scanned for additional publications. In order to
form a highly sensitive search strategy, there were no
restrictions on publications t a t u s ,o rs t u d yd e s i g n .
Although no language restrictions were imposed initially,
for the full-text review and final analysis, our resources
only permitted the review of articles published in the Eng-
lish and Chinese language. Letters, conference abstracts
and grey literature to the journal editors were excluded
because of the limited data presented.
From the studies obtained in the above search, only
those meeting the following criteria were qualified for
subsequent analyses: Chinese and English languages, any
study designed with at least thirty patients, reporting all-
comers populations with suspicious breast lesion after
clinic screening. The index biopsy method is fine-needle
aspiration biopsy (FNAB) with or without image-guide.
Two reviewers (Yinghua Yu, Wei Wei) selected eligible
studies independently. Discrepancies were solved by
discussion.
Data extraction and quality assessment
Data extraction was performed independently by two
reviewers (Yinghua Yu, Wei Wei)). The two reviewers
were blinded to publication details, and all extracted data
had to be agreed upon by them. Data retrieved from the
reports including study design, participant characteristics,
lesion size, FNAB procedures, outcomes measurement,
publication year, and methodological quality. The num-
bers of true-positive, false-positive, false-negative, and
true-negative results are displayed for each study in
Table 1.
We assessed the methodological quality of the studies
using guidelines published by the quality assessment for
studies of diagnostic accuracy (QUADAS) tool [9] [i.e.
appraisal by use of empirical evidence, expert opinion, and
formal consensus to assess the quality of primary studies
of diagnostic accuracy]. In addition, for each study the fol-
lowing characteristics of study design were also retrieved:
(1) needle gauge (21 gauge vs other size gauge); (2) gui-
dance systems (with ultrasound or stereotactic guidance vs
without image guidance); (3) prospective data collection,
and (4) geographic location; (5) reference standard (histo-
pathology only or not). If no data on the above criteria
were reported in the primary studies, we requested the
information from the authors. If the authors did not
respond to our letters, the “unknown” items were treated
as “no.”
Statistical analysis
We used standard methods recommended for meta-ana-
lyses of diagnostic test evaluations [10]. Analyses were
performed using RevMan5 software (the Cochrane Infor-
mation Management System (IMS)), STATA version
10.0 (STATA Corporation, TX, USA) and Meta-DiSc (for
Windows; XI Cochrane Colloquium; Barcelona, Spain).
We categorized the cytological results according to
The National Cancer Institute recommendation for the
diagnosis of breast aspiration cytology:
￿ Cl = unsatisfactory.
￿ C2 = cells present all benign; no suspicious features.
￿ C3 = cells suspicious but probably benign.
￿ C4 = cells suspicious but probably malignant.
￿ C5 = Definitely malignant.
This category’ is used when the degree of diagnostic
certainty is such that the pathologist would be happy for
the patient to undergo major breast surgery on the basis
of the cytology sample alone.
We classified the results of FNAB as positive (including
class C3, C4, C5) and negative (C2) adapted from Burapa
Kanchanabat [11] and Etta D. Pisano [12]. C1 was tem-
porarily exluded from this classification. Our reason for
this classification is that solid masses with a FNAB result
of intermediate classification (C3, C4,) require other diag-
nostic procedures to minimized the underestimation.
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Page 2 of 14Table 1 Summary of including studies (Insufficient Samples Excluded in test result)
study year reference standard test result patients (number) QUADAS score
TP FP FN TN
Walker et al.[33] 1998 his 91 0 0 19 110 13
Kanchanabat et al.[11] 2000 his/imag and clin 8 8 0 26 42 10
Pisano et al.[12] 2001 his/imag and clin 59 18 17 183 277 11
Lumachi et al.[34] 1999 his 55 0 2 5 62 10
Farshid et al.[35] 2008 his/imag and clin 91 120 2 880 1093 11
Dennison et al.[36] 2003 his/imag and clin 95 0 10 38 143 10
Gent et al.[37] 1986 his 39 7 1 109 156 13
Wanebo et al.[38] 1983 his 123 8 1 102 234 13
Apesteguia et al.[39] 1997 his/imag and clin 2 2 0 107 111 11
Manheimer et al.[40] 1977 his 79 2 11 35 127 11
Janet et al.[41] 2010 his/imag and clin 11 0 4 135 150 9
Drew et al.[42] 1999 his/imag and clin 102 4 27 130 263 8
Masood et al.[43] 1991 his 17 0 3 71 91 8
Ishikawa et al.[44] 2007 his 138 4 4 178 324 12
Harvey et al.[45] 1996 his/imag and clin 14 37 13 32 96 8
Leifland et al.[46] 2003 his 353 11 52 27 443 11
Okamoto et al.[47] 1998 his/imag and clin 5 1 1 125 132 11
Rubin et al.[48] 1997 his/imag and clin 34 4 0 27 65 10
Sauer et al.[32] 2003 his/imag and clin 360 21 47 321 749 11
Li et al.[49] 2008 his 129 1 22 108 260 9
Wang et al.[50] 2010 his 110 2 7 55 174 13
Yang et al.[51] 2010 his 79 0 4 259 342 11
Liu et al.[52] 2000 his 205 1 12 194 412 10
Zhao et al.[53] 2009 his 218 10 6 241 475 11
Zhan et al.[54] 2007 his 32 2 0 44 78 9
Gao et al.[55] 2005 his 169 0 27 85 281 11
Lu et al.[56] 2010 his 102 0 33 48 183 10
Liu et al.[57] 2010 his 5 1 1 125 132 11
Zhang et al.[58] 2008 his 39 6 4 53 102 11
Zhang et al.[59] 2006 his 21 2 3 31 57 9
Tang et al.[60] 1987 his 144 2 13 144 303 11
Wang et al.[61] 1995 his 25 0 2 22 49 10
Ma et al.[62] 2010 his 56 0 2 99 157 8
Wang et al.[63] 2010 his 96 12 4 498 610 8
Wang et al.[64] 1981 his 442 43 60 479 1024 10
Wei et al.[65] 2007 his 91 4 2 78 175 12
Tao et al.[66] 2004 his 655 5 14 2027 2701 12
Wang et al.[67] 2005 his 99 5 0 207 311 11
Chen et al.[68] 2010 his 66 1 9 176 252 8
Zeng et al.[69] 1999 his 94 1 2 66 163 11
Jia et al.[70] 1986 his 49 0 1 50 100 9
Ma et al.[71] 2010 his 68 0 4 291 363 10
Huang et al.[72] 2003 his 305 31 54 436 826 11
Zhang et al.[73] 1996 his 21 1 2 40 64 9
Yu et al.[74] 2006 his 1620 116 33 359 2128 11
Jiang et al.[75] 2008 his 66 1 9 176 252 11
His: histopathology; imag and clin:imaging and clinical follow-up; TP:true positive; FP: false positive; FN:false negative; TN: true negative.
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for each study: sensitivity; specificity; diagnostic odds
ratio (DOR); positive likelihood ratio (PLR) and negative
likelihood ratio (NLR). As for unsatisfactory samples
(C1), it includes disfigured cellular morphology that can-
not be interpreted and fewer than five epithelial cell
groups. Disputes about unsatisfactory samples were
among these studies on account of following therapeutic
decisions. In most of the studies, unsatisfactory samples
were excluded from analysis while considered to be posi-
tive in a study [12]. Since unsatisfactory samples played
important roles on therapeutic decisions, we also
assessed the sensitivity and specificity for the studies
which reported unsatisfactory samples (unsatisfactory
samples considered to be positive in our classification)
and underestimation rate of unsatisfactory samples.
The analysis was based on a summary receiver operating
characteristic (SROC) curve [13,14]. Sensitivity and specifi-
city for the single test threshold identified for each study
were used to plot an SROC curve. Random-effects model
was used to calculate the average sensitivity, specificity,
and the other measures across studies [15].
The term heterogeneity when used in relation to meta-
analyses refers to the degree of variability in results across
studies. We used the X2 and Fisher exact tests to detect
statistically significant heterogeneity. To assess the effects
of QUADAS scores on the diagnostic ability of FNAB, we
included it as covariates in univariate meta-regression ana-
lysis (inverse variance weighted). We also analyzed the
effects of other covariates on DOR (ie, publication year,
guidance systems, 21 or other size needle gauge, different
reference standard, prospective data collection, and differ-
ent geographic location). The relative DOR (RDOR) was
calculated according to standard methods to analyze the
change in diagnostic precision in the study per unit
increase in the covariate [16,17]. Since publication bias is
of concern for meta-analyses of diagnostic studies, we
tested for the potential presence of this bias using funnel
plots [18].
Results
After independent review, 59 publications dealing FNAB
for the diagnosis of breast cancer were considered to be
eligible for inclusion in the analysis. Of these publica-
tions, eight studies [19-26] were excluded because FNAB
was performed only in breast cancer patients, two studies
[27,28] were excluded because they evaluated the role of
FNAB in diagnosis of axillary lymph nodes, two studies
[29,30] were excluded because they did not allow the cal-
culation of sensitivity or specificity or underestimate rate,
one studies [31] were excluded because its data had been
included as a part of the latest study [32]. Subsequently,
46 studies [11,12,32-75] including 7207 patients with
breast cancer or suspicious features and 9435 patients
with benign mass were available for analysis, and the
clinical characteristics of these studies, along with QUA-
DAS scores, are outlined in Table 1. In addition, we
derived relative data about unsatisfactory samples from
11 [11,12,32,33,35,37-39,44,46,50] studies in table 2.
Study characteristics and quality of studies
As shown in Table 1 and Table 3 the average sample
size of the included studies was 362 patients (range, 42
to 2128). Twenty-night studies were performed in Asia;
Seventeen studies were conducted in NA (Canada and
USA) and Europe. With the exception of one study
which was multicenter [12], the others were single cen-
ter. Most studies were case series (41 retrospective, 5
prospective).
The age of patients ranged from 26 to 87 years. Risk fac-
tors for cancer in the selected population, i.e., family his-
tory, genetic predisposition, menopausal status, and/or
prior high risk lesions, were rarely reported. Needle size
has varied from 20 to 25 gauge in these studies, 15 studies
used 21-gauge size while the others used 20, 22, 23, 25
size or didn’t mentioned it. Four studies used stereotactic
guidance systems; five studies used ultrasound systems;
four studies used stereotactic or ultrasound guidance sys-
tems according to the breast mass; the rest studies per-
formed FNAB without any kind of imaged guidance
systems. Two outcome measurements were adopted by
these studies. As histopathologic results from surgical
biopsy was regarded as gold standard in this field, patients
with malignant lesions, cells suspicious, or when
requested, subsequently underwent open surgery in all
these studies. In case of benign lesions (breast cysts and a
benign cytological result from low-risk patients), clinical
and imaged follow-up at least 6 months was adopted by
some studies while most of the studies still have involved
Table 2 Test result of studies (Insufficient Samples
Classified as Positive)
study test result Patients number
TP FP FN TN
Walker et al.[33] 95 11 0 19 125
Kanchanabat et al.[11] 8 13 0 26 47
Pisano et al.[12] 80 149 17 183 429
Farshid et al.[35] 92 173 2 880 1147
Gent et al.[37] 39 38 1 109 187
Wanebo et al.[38] 135 18 1 102 256
Apesteguia et al.[39] 2 36 0 107 145
Ishikawa et al.[44] 156 44 4 178 382
Leifland et al.[46] 406 37 52 27 522
Sauer et al.[32] 382 82 47 321 832
Wang et al.[50] 119 5 7 55 186
TP:true positive; FP: false positive; FN:false negative; TN: true negative.
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study study design
prospective
geographic location
Asia
21 needle
gauge
Apply imaging guidance
systems
histopathology standard
only
Walker et al.[33] yes no yes no Yes
Kanchanabat et al.
[11]
yes yes no no no
Pisano et al.[12] yes no no yes no
Lumachi et al.[34] no no not mention yes yes
Farshid et al.[35] yes no not mention no no
Dennison et al.[36] yes no yes no no
Gent et al.[37] no no no yes yes
Wanebo et al.[38] no no no yes yes
Apesteguia et al.
[39]
no no no yes no
Manheimer et al.
[40]
no no no no yes
Janet et al.[41] no yes no no no
Drew et al.[42] no no not mention no no
Masood et al.[43] no no not mention no yes
Ishikawa et al.[44] no yes no no yes
Harvey et al.[45] no no not mention yes no
Leifland et al.[46] no no yes yes yes
Okamoto et al.[47] no yes yes yes no
Rubin et al.[48] no no not mention no no
Sauer et al.[32] no no not mention yes no
Li et al.[49] no yes not mention no yes
Wang et al.[50] no yes not mention no yes
Yang et al.[51] no yes not mention no yes
Liu et al.[52] no yes not mention no yes
Zhao et al.[53] no yes yes no yes
Zhan et al.[54] no yes yes no yes
Gao et al.[55] no yes yes no yes
Lu et al.[56] no yes no yes yes
Liu et al.[57] no yes yes yes yes
Zhang et al.[58] no yes no no yes
Zhang et al.[59] no yes yes yes yes
Tang et al.[60] no yes yes no yes
Wang et al.[61] no yes no yes yes
Ma et al.[62] no yes no no yes
Wang et al.[63] no yes no no yes
Wang et al.[64] no yes yes no yes
Wei et al.[65] no yes yes no yes
Tao et al.[66] no yes no no yes
Wang et al.[67] no yes yes no yes
Chen et al.[68] no yes yes no yes
Zeng et al.[69] no yes no no yes
Jia et al.[70] no yes yes no yes
Ma et al.[71] no yes no no yes
Huang et al.[72] no yes yes no yes
Zhang et al.[73] no yes yes no yes
Yu et al.[74] no yes yes no yes
Jiang et al.[75] no yes yes no yes
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Page 5 of 14comparison of FNAB benign findings with histopathologic
results from core-needle biopsy or open surgical biopsy.
We assessed the quality of the studies using QUADAS.
Out of 14 QUADAS items, item 1 (spectrum composition)
and item 2 (selection criteria) are about the variability of
studies, item 8 (index test execution), 9 (reference stan-
dard execution) and 13 (uninterpretable test results) are
about the quality of reporting, the rest of the items are
about the bias of studies. If criterion was fulfilled, the item
was signed “yes"; if not, the item was signed “no"; if study
did not report clearly and we could not request the infor-
mation from the authors, the item was signed “unknown”.
As shown in Table 4, item 1 and 2 were 91% and 100%
fulfilled by studies respectively; item 8, 9, 13 were 80%,
100%, 24%; in the rest of the items assessed bias reached a
high level, except item 11 (reference standard review bias)
and 14 (withdrawals).
Diagnostic accuracy
Figure 1 shows the forest plot of sensitivity and specificity
for FNAB in the diagnosis of breast cancer (C1 was tem-
porarily exluded). The sensitivity ranged from 0.52 to
1.00 (mean, 0.927; 95% confidence interval [CI], 0.921 to
0.933), and specificity ranged from 0.46 to 1.00 (mean,
0.948; 95% CI, 0.943 to 0.952). We also noted that PLR
was 25.72 (95% CI, 17.35 to 28.13), NLR was 0.08 (95%
CI, 0.06 to 0.11), and DOR was 429.73 (95% CI, 241.75 to
763.87). X2 values of sensitivity, specificity, PLR, NLR,
and DOR were 437.15 (p < 0.001), 840.00 (p < 0.001),
653.52 (p < 0.001), 464.80 (p < 0.001), and 396.91 (p <
0.001), respectively, with all indicating a significant het-
erogeneity between studies.
The SROC curve presents a global summary of test
performance, and shows the tradeoff between sensitivity
and specificity. A graph of the SROC curve for the biopsy
results of FNAB (C1 was temporarily exluded) showing
true-positive rates vs false-positive rates from individual
studies is shown in Figure 2. Our data showed that the
SROC curve is positioned near the desirable upper left
corner of the SROC curve, and that the maximum joint
sensitivity and specificity (ie, the Q-value) was 0.948;
while the area under the curve (AUC) was 0.986, indicat-
ing a high level of overall accuracy.
Since unsatisfactory samples played important roles on
therapeutic decisions, we assessed the pooled sensitivity
and specificity for FNAB in the diagnosis of breast can-
cer in these 11 studies [11,12,32,33,35,37-39,44,46,50],
which reported unsatisfactory samples (C1 was consid-
ered to be positive in this classification). As Figure 3
shows, the pooled sensitivity and specificity for this
group were 0.920 (95% CI, 0.906 to 0.933; X2 = 71.53,
p < 0.001) and 0.768 (95% CI, 0.751 to 0.784; X2 =
163.02, p < 0.001) respectively. This graph of the SROC
curve is shown in Figure 4. The maximum joint sensitiv-
ity and specificity was 0.815; while the area under the
curve (AUC) was 0.884. In addition, we calculated and
displayed the underestimation rates of unsatisfactory
samples between FNAB and histopathologic standard in
table 5. The pooled proportion of these unsatisfactory
samples that were subsequently upgraded to various
grade cancers was 27.5% (95% CI, 0.221 to 0.296), X2
values was 159.85 (p < 0.001). This p-values also indi-
cated significant heterogeneity between studies.
Multiple regression analysis and publication bias
We used meta-regression to assess the different aspects
among 46 studies: with or without 21-gauge, with or
without imaging guidance systems, standard reference
adopted histopathology only, located in Asia, prospective
designs and QUADAS scores. Quality scoring was done
by the use of QUADAS [76], in which a score of 1 was
g i v e nw h e nac r i t e r i o nw a sf u lfilled, 0 if a criterion was
unclear, and -1 if the criterion was not achieved. As was
shown in table 1, the studies were with relative high
quality if its score was more than ten. These scores
were used in the meta-regression analysis to assess the
effect of study quality on the RDOR of FNAB in the
diagnosis of breast mass. The table 6 showed that
excepted two aspects (with or without imaging guidance
systems, standard reference adopted histopathology
only), the rest aspects mentioned above did not substan-
tially affect the diagnostic accuracy as their differences
did not reach statistical significance (p > 0.05).
The funnel plots for publication bias (Figure 5)
showed large asymmetry. These results indicated a
potential for publication bias.
Table 4 methodological quality of 46 studies
QUADAS item
12 34567891 0 1 1 1 2 1 3 1 4
Yes(n) 42 46 46 40 46 35 46 37 46 46 7 39 11 13
No(n) 4 0 0 0 0 11 0 5 0 0 0 0 0 3
Unknown(n) 0 0 0 6 0 0 0 4 0 0 39 7 35 30
Yes(%) 91 100 100 87 100 76 100 80 100 100 15 85 24 28
n: number of studies
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Page 6 of 14Figure 1 Forest plot of estimates of sensitivity and specificity for FNAB (C1 was temporarily exluded) in the diagnosis of breast
cancer. The point estimates of sensitivity and specificity from each study are shown as solid circles. Error bars are 95% confidence intervals. The
authors’ names indicate the studies.
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Our current meta-analysis presented the high level diag-
nostic accuracy of Fine-needle aspiration biopsy
(FNAB). In our first classification (C1 was temporarily
exluded as most studies did.), the sensitivity rate was
92.7% and the specified rate was nearly 94.8%. The
SROC curve showed the maximum joint sensitivity and
specificity (i.e. the Q-value) was 0.948; while the area
under the curve (AUC) was 0.986, presenting excellent
level of overall accuracy.
The DOR is a single indicator of test accuracy [77] that
combines the data from sensitivity and specificity into a
single number. The DOR of a test is the ratio of the odds
of positive test results in the patient with disease relative
to the odds of positive test results in the patient without
disease. The value of a DOR ranges from 0 to infinity,
with higher values indicating better discriminatory test
performance (i.e. higher accuracy). A DOR of 1.0 indicates
that a test does not discriminate between patients with the
disorder and those without it. In the present meta-analysis,
we have found that the mean DOR was 429.73, also indi-
cating a high level of overall accuracy.
S i n c et h eS R O Cc u r v ea n dt h eD O Ra r en o te a s yt o
interpret and use in clinical practice, and since likelihood
ratios are considered to be more clinically meaningful
[78,79], we also presented both PLR and NLR as our
measures of diagnostic accuracy. Likelihood ratios of >
10 or < 0.1 generate large and often conclusive shifts
from pre-test to post-test probability (indicating high
accuracy) [79]. In our first classification, PLR value of
25.72 suggests that patients with various grade cancers
have an approximately 26-fold higher chance of being
FNAB result-positive compared with patients with benign
breast lesion. This high probability would be considered
high enough to begin surgical treatment or other therapy.
On the other hand, NLR was found to be 0.08 in our
Figure 2 SROC curves for FANB (C1 was temporarily exluded). Each study is represented by each solid circle in the meta-analysis. The size
of the solid circle indicates the size of each study. SROC curves summarize the overall diagnostic accuracy.
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Page 8 of 14current meta-analysis. If the FNAB result was negative,
the probability that this patient has breast carcinoma is
approximately 8%.
It should be emphasized that we used the approach of
Burapa Kanchanabat [11] and Etta D. Pisano [12] for
evaluating the diagnostic performance of FNAB (1.
unsatisfactory samples was temporarily excluded; 2.
unsatisfactory samples was classified as positive). In our
first classification, unsatisfactory samples (C1) was
exluded as most studies did. In our second classification,
Figure 3 Forest plot of estimates of sensitivity and specificity for FNAB in 11 studies which reported insufficient samples. Insufficient
samples considered to be positive.
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Page 9 of 14Inadequate cytological material have to be interpreted as
“positive”. Because treating the unsatisfactory result as a
negative outcome is a poor policy that has the potential
to cause harm to patients and delay the diagnosis of
breast cancer. On the purpose of minimizing the chance
of a missed diagnosis of breast cancer, certain discre-
pancies between FNAB and open biopsy (e.g. cytological
results including C3, C4, C5 on FNAB and atypical
hyperplasia or various grades cancer on open biopsy)
were considered as agreements and needed further man-
agement. The reclassified agreement rate is therefore a
clinically relevant and pragmatic estimate for the accor-
dance between FNAB and actual disease status.
Breast cancer was present in certain proportion of the
inadequate FNAB specimens. Since unsatisfactory sam-
ples (C1) played important roles in influencing diagnos-
tic accuracy of FNAB, we also assessed the pooled
sensitivity and specificity for FNAB in the other classifi-
cation (unsatisfactory samples were regarded as positive)
and the underestimation rate of unsatisfactory samples.
This pooled sensitivity (92.7%) was similar with the sen-
sitivity (92.0%) that mentioned above in our first classifi-
cation (unsatisfactory samples was exluded) while the
pooled specificity (76.8%) was lower than the specificity
(94.8%) above. This change may be due to the underes-
timation rate of inadequate samples which was currently
Figure 4 SROC curves for FANB of 11 studies which reported insufficient samples (insufficient samples was considered to be positive).
Each study is represented by each solid circle in the meta-analysis. The size of the solid circle indicates the size of each study. SROC curves
summarize the overall diagnostic accuracy.
Table 5 Summary underestimation rate of unsatisfactory samples using meta-analysis
n a b pooled under-estimation rate 95%CI X
2 P-value
unsatisfactory Samples 11 140 545 25.7% 0.221-0.296 159.85 p < 0.001
n = number of studies; a = number of breast cancer or Low grade cancers; b = total number of unsatisfactory Samples;
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Page 10 of 14assessed in our study. This pooled unsatisfactory sam-
ples’ underestimate rate was 27.5% which was higher
than the value (8.5%) reported by H.C.Lee [80]. How-
ever, we included more recent related studies and more
patients than H.C.Lee did. Our underestimate rate indi-
cated that 27.5% of the patients with a diagnosis of
inadequate samples for cytological analysis will prove to
have various grades breast cancer. This rate was not low
enough to rule out breast cancer. So, in most of these
cases, an additional managemant such as core biopsies
or surgical procedure will then be necessary.
On the whole, the quality of the included studies is
higher than median level according to QUADAS. Many
studies did not reach item 11 (reference standard review
bias), 13 (uninterpretable test results) or 14 (withdrawals).
According to QUADAS items and studies’ detail analysis,
most studies did not mention blinding results interpreted,
uninterpretable test results or explained withdrawals
which did not match item 11, 13 and 14. These bias would
affect the analysis of accuracy of FNAB.
An exploration of the reasons for heterogeneity rather
than the computation of a single summary measure was
an important goal of meta-analysis [81]. In our meta-
analysis, QUADAS scores were used in the meta-regres-
sion analysis to assess the effect of study quality on
RDOR. We did not observe that the studies with rela-
tively higher quality (QUADAS score of ≥10) had better
test performances than those with lower quality.
Although we found a significant heterogeneity for sen-
sitivity, specificity, PLR, NLR and DOR among the stu-
dies analyzed, meta-regression results showed that 3
different aspects among 46 studies (such as needle size,
study locations and prospective/retrospective designs)
didn’t reach statistical significance, indicating that these
Table 6 meta-regression of the effects of six different studies’ aspects on diagnosis value of FNAB
Covariates Number of studies Coefficient RDOR 95%CI P-value
QUADAS ≥ 10 34 0.747 2.11 0.60-7.47 0.2389
21-gauge 19 -0.705 0.49 0.16-1.53 0.2149
imaging guidance systems 13 -1.383 0.25 0.07-0.95 0.0417
histopathology only 35 1.705 5.5 1.04-29.08 0.0451
prospective 5 0.74 2.1 0.25-17.36 0.4829
Asia 31 0.433 1.56 0.33-7.43 0.5696
Begg's funnel plot with pseudo 95% confidence limits
l
o
g
s.e. of: log
0 .5 1 1.5 2
0
5
10
Figure 5 Funnel graph for the assessment of potential publication bias in FNAB. The funnel graph plots the log of the DOR against the SE
of the log of the DOR (an indicator of sample size). Forty-six circle represents forty-six studies in the meta-analysis. The line in the centre
indicates the summary diagnostic odds ratio.
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On the other hand, 2 different aspects such as guidance
systems (with ultrasound or stereotactic guidance vs
without imaging guidance) and reference standard (histo-
pathology only or not) affect the diagnostic accuracy in
great part. These may be due to the following reasons.
First, fine-needle aspiration biopsy without imaging gui-
dance is not suitable for patients with ill-defined masses
because the aspiration cannot be done at the exact posi-
tion and the cytological result may not represent the true
nature of the mass. In other words, breast lesions could
be definitely localized by imaging guidance then FNAB
could be done. FNAB with imaging guidance system can
make a favorite diagnosic accuracy. Second, there were
the combined two standard methods adopted by some
included studies, surgery biopsy for suspicious lesion and
imaging or clinic follow-up for benign cytological result
from low-risk patients. Moreover, the time of follow-up
is different from each other (range from 6-24 months).
As a result, misclassification may occur easier in this two
different reference standard situation than in that histo-
pathologic is the only reference standard.
Apart for having a comprehensive search strategy, our
study assessed the FNAB diagnosis accuracy in all direc-
tions, such as sensitivity, specificity, PLR, NLR, DOR,
SROC curve and AUC. In addition, we assessed the influ-
ence of unsatisfactory samples on FNAB diagnosis accu-
racy. Heterogeneity and potential publication bias were
also explored in accordance with published guidelines.
However, our systematic review had some limitations.
Only including English and Chinese language studies and
the lack of conference abstracts, letters to editors might
have led to publication bias.
Conclusion
On the whole, our current evidence shows that fine-nee-
dle aspiration biopsy (FNAB) is an accurate biopsy for
evaluating breast malignancy if rigorous criteria are used.
With high sensitivity and specificity, most benign and
malignant breast lesions can be reliably diagnosed by
FNAB. FNAB may provide a favorable screening method
and permit an improvement of treatment planning. With
the introduction of imaging guided methods for percuta-
neous sampling of nonpalpable lesions, FNAB can be
used more widely in the evaluation of breast lesions
However, as unsatisfactory samples’ underestimate rate
(27.5%) is not low enough to rule out malignant, the
result of C1 for cytological analysis in FNAB warrants
futher invasive procedures including core biopsies or
open surgical biopsy in order to minimize the chance of
missed diagnosis of breast cancer. Fine needle aspiration
continues to be an acceptable and reliable procedure for
the preoperative diagnosis of breast lesions, particularly
in developing countries.
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